Latest news with #Satellos
National Post
22-05-2025
- Business
- National Post
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
Article content Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids Potential trend to improved grip strength observed, with average strength across the study participants doubling from ~2kg to ~4kg Study participants will have the option to enroll into an 11-month, long-term follow-up study Satellos plans to advance SAT-3247 into a placebo-controlled Phase 2 trial following additional data analysis and regulatory engagement Article content Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD. Article content 'We have gained valuable insights from this study of SAT-3247, and we are deeply grateful to the participants,' said Satellos Co-founder and Chief Executive Officer Frank Gleeson. 'Given the short 28-day treatment window, the severity and variability of disease in this population, who have limited remaining muscle, we are encouraged by these initial data — particularly, the apparent trend of improved grip strength. Improvements in muscle strength have consistently been an early signal of a possible drug effect in our preclinical studies, where treatment with SAT-3247 led to notable increases in muscle force in both rodent and canine models of DMD. We believe the findings from this Phase 1b study support our plan to advance SAT-3247 into a placebo-controlled Phase 2 trial. We look forward to engaging with regulators and sharing more about our next steps.' Article content SAT-3247 is designed to address progressive muscle loss in DMD patients by aiming to restore regeneration in response to damage. The Phase 1b open-label trial of SAT-3247 was conducted in adults with DMD, with the primary endpoint being safety and tolerability. As additional endpoints, the study evaluated a number of exploratory measurements of a possible drug effect. The study focused on adults, a demographic representing individuals who have reached the later stages of the disease, where clinical management becomes increasingly complex and long-term survival is less common. All participants were maintained on their prescribed daily course of steroids during the study. Article content Summary of clinical results: Article content SAT-3247 appeared to be safe and well tolerated in all study participants. The PK profile of SAT-3247 translated as expected to DMD patients on steroids, an important objective of the study. Grip strength was measured using the standardized MyoGrip measurement device. Across all study participants, an average doubling of strength from ~2kg to ~4kg was observed. Study participants appeared to remain stable in other exploratory measurement areas. Article content Satellos plans to begin an 11-month follow-up study, which has already received ethics committee approval in Australia. First-patient dosing is expected in Q3 2025, pending qualification of the clinical site. The study will incorporate MRI imaging to assess possible changes in muscle and will measure grip strength every three months to evaluate whether the observed improvements continue, as well as additional functional and biomarker measurements. Article content Satellos believes the Phase 1b findings support advancing SAT-3247 into a global, placebo-controlled Phase 2 proof-of-concept study in pediatric patients, for which global regulatory submissions are planned for the third quarter of 2025. Article content The Phase 1 clinical trial of SAT-3247 was comprised of two components. In the first component, Phase 1a, 72 healthy volunteers were enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design study to assess the safety and pharmacokinetic properties of SAT-3247. Participants were randomized across five SAD cohorts, four MAD cohorts, and one food effect cohort. In the second component, the Phase 1b portion of the trial, five adult volunteers with genetically confirmed DMD, all of whom were receiving their prescribed steroid treatments, were enrolled in a 28-day open-label single-dose cohort study to assess safety and pharmacokinetic properties and assess a range of exploratory measures including potential pharmacodynamic markers. Article content About SAT-3247 Article content SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne muscular dystrophy and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, expected timing for a Phase 2 clinical trial and the intended Phase 1b long-term follow-up study; statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. Article content Article content Article content Article content Article content
Business Wire
22-05-2025
- Health
- Business Wire
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD. 'We have gained valuable insights from this study of SAT-3247, and we are deeply grateful to the participants,' said Satellos Co-founder and Chief Executive Officer Frank Gleeson. 'Given the short 28-day treatment window, the severity and variability of disease in this population, who have limited remaining muscle, we are encouraged by these initial data — particularly, the apparent trend of improved grip strength. Improvements in muscle strength have consistently been an early signal of a possible drug effect in our preclinical studies, where treatment with SAT-3247 led to notable increases in muscle force in both rodent and canine models of DMD. We believe the findings from this Phase 1b study support our plan to advance SAT-3247 into a placebo-controlled Phase 2 trial. We look forward to engaging with regulators and sharing more about our next steps.' SAT-3247 is designed to address progressive muscle loss in DMD patients by aiming to restore regeneration in response to damage. The Phase 1b open-label trial of SAT-3247 was conducted in adults with DMD, with the primary endpoint being safety and tolerability. As additional endpoints, the study evaluated a number of exploratory measurements of a possible drug effect. The study focused on adults, a demographic representing individuals who have reached the later stages of the disease, where clinical management becomes increasingly complex and long-term survival is less common. All participants were maintained on their prescribed daily course of steroids during the study. Summary of clinical results: SAT-3247 appeared to be safe and well tolerated in all study participants. The PK profile of SAT-3247 translated as expected to DMD patients on steroids, an important objective of the study. Grip strength was measured using the standardized MyoGrip measurement device. Across all study participants, an average doubling of strength from ~2kg to ~4kg was observed. Study participants appeared to remain stable in other exploratory measurement areas. Satellos plans to begin an 11-month follow-up study, which has already received ethics committee approval in Australia. First-patient dosing is expected in Q3 2025, pending qualification of the clinical site. The study will incorporate MRI imaging to assess possible changes in muscle and will measure grip strength every three months to evaluate whether the observed improvements continue, as well as additional functional and biomarker measurements. Satellos believes the Phase 1b findings support advancing SAT-3247 into a global, placebo-controlled Phase 2 proof-of-concept study in pediatric patients, for which global regulatory submissions are planned for the third quarter of 2025. About Phase 1 DMD Trial with SAT-3247 The Phase 1 clinical trial of SAT-3247 was comprised of two components. In the first component, Phase 1a, 72 healthy volunteers were enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design study to assess the safety and pharmacokinetic properties of SAT-3247. Participants were randomized across five SAD cohorts, four MAD cohorts, and one food effect cohort. In the second component, the Phase 1b portion of the trial, five adult volunteers with genetically confirmed DMD, all of whom were receiving their prescribed steroid treatments, were enrolled in a 28-day open-label single-dose cohort study to assess safety and pharmacokinetic properties and assess a range of exploratory measures including potential pharmacodynamic markers. About SAT-3247 SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne muscular dystrophy and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status. About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, expected timing for a Phase 2 clinical trial and the intended Phase 1b long-term follow-up study; statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
National Post
13-05-2025
- Business
- National Post
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
Article content Article content – Profile of SAT-3247, presented at the Muscular Dystrophy Association (MDA) Conference, demonstrated the drug to be safe and well tolerated with a predictable pharmacokinetic (PK) profile in healthy volunteers Article content – Global regulatory filings to obtain approvals to initiate a Ph 2 randomized, placebo-controlled proof-of-concept clinical (POC) trial in pediatric DMD patients expected to be submitted in Q3 2025 Article content – Funds available: $41.2 million (in $U.S.) as of March 31, 2025, expected to be sufficient to fund company operations, including study costs through completion of the planned Phase 2 POC clinical trial Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced its financial results and corporate highlights for the first quarter ended March 31, 2025. Article content 'We are very pleased with our continued progress in the advancement of SAT-3247,' said Frank Gleeson, Co-founder and Chief Executive Officer. 'We plan to share data from our Phase 1b study in adult DMD patients in Q2 2025, marking another key development milestone. As a Company, we believe we are well positioned to advance our novel drug into a randomized, placebo-controlled Phase 2 POC trial in pediatric DMD patients as our next major development step. This study will be designed to further assess the safety of SAT-3247 in a key pediatric population, while exploring its possible utility in restoring the body's ability to repair and regenerate damaged or lost muscle.' Article content On March 19, 2025, Satellos presented initial Phase 1a data at the MDA Clinical & Scientific Conference in Dallas, TX. The data showed SAT-3247 was safe, well tolerated, and consistent with the Company's preclinical PK predictions, following both single and repeat dose administration. Phase 1b trial in up to 10 adult DMD patients has completed enrollment. The study is a 28-day, open-label design to assess safety, PK, and exploratory pharmacodynamic markers. Satellos expects to complete analysis and report full Phase 1 data in Q2 2025. Long-term follow-up clinical study, enabling treatment of Ph 1b patients for up to an additional 11 months, received regulatory approved in Australia. Regulatory filings seeking approval for a global Ph 2 randomized, placebo-controlled POC trial in pediatric DMD patients planned for Q3 2025. Article content Effective Jan. 1, 2025, Satellos changed its presentation currency from the Canadian dollar to the United States dollar (U.S. dollar). The change in presentation currency was made to better reflect the Company's business activities and to improve investor's ability to compare the Company's financial results with other publicly traded business in the industry. Article content For the year ended Dec. 31, 2024, and for all prior periods, Satellos presented its financial statements in Canadian dollars. The comparative figures disclosed in this press release have been retrospectively changed to reflect the change in presentation currency to the U.S. dollar, as if the U.S. dollar had been used as the presentation currency for all prior periods. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. Article content Satellos had cash and cash equivalents and short-term investments of $41.2 million as of March 31, 2025, compared with $48.5 million at Dec. 31, 2024. The decrease in funds available is due to the increase in net loss in the current year period, as well as increased deposits related to the planned Phase 2 clinical trial. Article content For the three months ended March 31, 2025, Satellos reported a net loss of $6.1 million ($0.04 loss per share), compared to a net loss of $5.1 million ($0.05 loss per share) for the three months ended March 31, 2024. The increase in net loss for the three months ended March 31, 2025, compared with the same period in 2024 was a result of increased research and development (R&D) expenses, as well as increased general and administrative (G&A) expenses. Article content R&D expenses increased by approximately $136 thousand to $4.5 million for the three months ended March 31, 2025, compared to $4.4 million for the three months ended March 31, 2024. The increase in R&D expenses was the result of increased clinical costs associated with the ongoing and planned clinical trials, partially offset by decreased CMC activities related to the process development and manufacturing of SAT-3247 for clinical use in the prior period and preclinical costs due to pre-IND enabling studies conducted to support the regulatory filing, and IND enabling studies for SAT-3247 as we prepared for clinical development in the prior period. Article content G&A expenses increased by approximately $215 thousand to $1.9 million for the three months ended March 31, 2025, as compared to $1.7 million for the three months ended March 31, 2024. The increase in general and administrative expenses in the current year period is primarily the result of higher salary and management fees related to changes in headcount to support expanded operations and non-cash stock-based compensation expense due to new grants issued in the current period. Article content The Satellos condensed consolidated interim financial statements for the three months ended March 31, 2025, and the related management discussion and analysis will be available on SEDAR+ at Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, expected timing for Phase 1 data; expected timing for additional regulatory filings; estimated runway based on cash on hand; statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; the utility of regenerating muscle by modulating polarity; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. Article content Article content Article content Article content Article content Article content
National Post
07-05-2025
- Business
- National Post
Satellos to Present at the CureDuchenne FUTURES National Conference
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, taking place in San Antonio, TX, from May 22 to 25. Article content Article content Satellos Co-founder and CEO Frank Gleeson will participate in the 'New Therapeutic Approaches' session on Sat., May 24 from 1:30-2:30 p.m. CT. Article content Event and registration information is available at: Article content About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content Article content Article content Article content Article content
National Post
29-04-2025
- Business
- National Post
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6. Article content Article content Satellos Co-founder and CEO Frank Gleeson will provide a presentation on May 5 and along with members of the management team, will participate in one-on-one meetings during the conference. Article content 2025 Bloom Burton & Co. Healthcare Investor Conference Format: Presentation and webcast Presenter: Frank Gleeson, President and CEO Date: Monday, May 5 Time: 11:30 a.m. ET Location: Metro Toronto Convention Centre Article content The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit Article content Article content Article content Article content Article content Article content
